Literature DB >> 4066047

Activity of 18 antimicrobial agents against multi-resistant strains of Staphylococcus aureus isolated from intensive care patients.

D Duncker, U Ullmann.   

Abstract

During an outbreak of infections with multiple-resistant Staphylococcus aureus, 22 strains were isolated from 12 patients between November 1983 and March 1984 on two surgical intensive care units at Kiel University Hospital. Susceptibility of all strains was tested with the disc diffusion method and a microdilution test using different inocula of 10(2) and 10(5) cfu/ml. All strains were resistant to beta-lactam antibiotics, including thienamycin as well as to gentamicin, clindamycin, doxycycline, erythromycin and fosfomycin. Rifampicin was the most active substance in terms of w/v, followed by fusidic acid, ciprofloxacin, vancomycin, and trimethoprim/sulfamethoxazole. Netilmicin and chloramphenicol showed only moderate activity in relation to the antibiotic breakpoint, but were considered sensitive according to the disc diffusion test. Caution should be reserved for the use of imipenem against multiply-resistant staphylococci.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4066047     DOI: 10.1007/BF01667220

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital.

Authors:  J J Klimek; F J Marsik; R C Bartlett; B Weir; P Shea; R Quintiliani
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

2.  'Methicillin resistant' Staphylococcus aureus infections during 1978-79: clinical and bacteriologic observations.

Authors:  H Giamarellou; M Papapetropoulou; G K Daikos
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

3.  In vitro activity of N-formimidoyl thienamycin and other beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; K A Fisher; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Studies on multi-antibiotic resistant strains of Staphylococcus aureus.

Authors:  H Chmel; A Person; F Tecson-Tumang
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies.

Authors:  K Crossley; D Loesch; B Landesman; K Mead; M Chern; R Strate
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

6.  Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection.

Authors:  R M Locksley; M L Cohen; T C Quinn; L S Tompkins; M B Coyle; J M Kirihara; G W Counts
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; I Cabezudo; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  W Graninger; T Leitha; M Havel; A Georgopoulos
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

9.  In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin.

Authors:  S Dixson; W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

10.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  1 in total

1.  The microbiological efficacy of the combination of fosfomycin and vancomycin against clinically relevant staphylococci.

Authors:  S Gatermann; E Schulz; R Marre
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.